NeurAxis (NRXS) Stock Price, News & Analysis

Company Overview

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Key Stats

• Today's Range: $2.62 to $2.70
• 50-Day Range: $2.29 to $3.20
• 52-Week Range: $1.33 to $6.20
• Volume: 57,602 shs
• Average Volume: 734,411 shs
• Market Capitalization: $18.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

NeurAxis Stock Analysis - MarketRank™

NeurAxis scored higher than 53% of companies evaluated by MarketBeat, and ranked 522nd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

NeurAxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

NeurAxis has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NeurAxis is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeurAxis is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.43% of the float of NeurAxis has been sold short.

Short Interest Ratio / Days to Cover

NeurAxis has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeurAxis has recently decreased by 12.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeurAxis does not currently pay a dividend.

Dividend Growth

NeurAxis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.43% of the float of NeurAxis has been sold short.

Short Interest Ratio / Days to Cover

NeurAxis has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeurAxis has recently decreased by 12.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for NRXS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, NeurAxis insiders have sold 131.00% more of their company's stock than they have bought. Specifically, they have bought $800,001.00 in company stock and sold $1,847,986.00 in company stock.

Percentage Held by Insiders

26.40% of the stock of NeurAxis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.77% of the stock of NeurAxis is held by institutions.

NRXS Stock Analysis - Frequently Asked Questions

How have NRXS shares performed this year?

NeurAxis' stock was trading at $2.35 at the beginning of 2025. Since then, NRXS shares have increased by 11.5% and is now trading at $2.62.

How were NeurAxis' earnings last quarter?

NeurAxis, Inc. (NASDAQ:NRXS) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.25) EPS for the quarter. The business earned $0.67 million during the quarter.

When did NeurAxis IPO?

NeurAxis (NRXS) raised $7 million in an IPO on Wednesday, August 9th 2023. The company issued 1,098,667 shares at $6.00 per share.

Who are NeurAxis' major shareholders?

Top institutional shareholders of NeurAxis include AIGH Capital Management LLC (5.54%) and Wealthcare Advisory Partners LLC (0.21%).
View institutional ownership trends.

How do I buy shares of NeurAxis?

Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeurAxis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeurAxis investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Outdoor (POWW), SPDR S&P 500 ETF Trust (SPY), TJX Companies (TJX) and ETRACS Crude Oil Shares Covered Call ETN (USOI).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 7/29/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NRXS
• CIK: 1933567
• Web: neuraxis.com
• Phone: (812) 689-0791
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NeurAxis: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +167.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.63 million
• Net Margins: -492.76%
• Pretax Margin: -341.35%
• Return on Equity: N/A
• Return on Assets: -641.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.24
• Quick Ratio: 0.23

Sales & Book Value

• Annual Sales: $2.93 million
• Price / Sales: 6.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.27) per share
• Price / Book: -9.70

Miscellaneous

• Outstanding Shares: 7,216,000
• Free Float: 6,085,000
• Market Cap: $18.91 million
• Optionable: Not Optionable
• Beta: 3.09